Dosing begins in 5-MeO-DMT trial for resistant depression
Beckley Psytech has confirmed it has dosed the first patient in its international Phase 2b study of BPL-003 – a novel synthetic intranasal formulation of 5-MeO-DMT – for Treatment Resistant Depression (TRD).
The trial is the largest ever efficacy study of 5-MeO-DMT (also known as Mebufotenin) and is taking place at 40 sites across six countries, with initial study results expected in 2024.
The multi-centre, quadruply-masked Phase 2b study aims to assess the efficacy and safety of different doses of BPL-003 in patients with Treatment Resistant Depression (TRD).
BPL-003 is Beckley Psytech’s patent-protected benzoate formulation of 5-MeO-DMT and is administered intranasally via an FDA-approved delivery device.READ MORE